The University of Southampton
University of Southampton Institutional Repository

The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review

Westlake, Sarah L., Colebatch, Alexandra N., Baird, Janis, Kiely, Patrick, Quinn, Mark, Choy, Ernest, Ostor, Andrew J.K. and Edwards, Christopher J. (2010) The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review Rheumatology, 49, (2), pp. 295-307. (doi:10.1093/rheumatology/kep366). (PMID:19946022).

Record type: Article

Abstract

Objectives: patients with RA have an increased prevalence of cardiovascular disease (CVD). This is due to traditional risk factors and the effects of chronic inflammation. MTX is the first-choice DMARD in RA. We performed a systematic literature review to determine whether MTX affects the risk of CVD in patients with RA.

Methods: we searched Medline, Embase, Cochrane database, database of abstracts of reviews of effects, health technology assessment and Science Citation Index from 1980 to 2008. Conference proceedings (British Society of Rheumatology, ACR and EULAR) were searched from 2005 to 2008. Papers were included if they assessed the relationship between MTX use and CVD in patients with RA. Two reviewers independently assessed each title and abstract for relevance and quality.

Results: a total of 2420 abstracts were identified, of which 18 fulfilled the inclusion criteria. Two studies assessed the relationship between MTX use and CVD mortality, one demonstrated a significant reduction in CVD mortality and the second a trend towards reduction. Five studies considered all-cause CVD morbidity. Four demonstrated a significant reduction in CVD morbidity and the fifth a trend towards reduction. MTX use in the year prior to the development of RA decreased the risk of CVD for 3–4 years. Four studies considered myocardial infarction, one demonstrated a decreased risk and three a trend towards decreased risk with MTX use.

Conclusion: the current evidence suggests that MTX use is associated with a reduced risk of CVD events in patients with RA. This suggests that reducing the inflammation in RA using MTX not only improves disease-specific outcomes but may also reduce collateral damage such as atherosclerosis

Full text not available from this repository.

More information

e-pub ahead of print date: 27 November 2009
Published date: February 2010
Keywords: rheumatoid arthritis, methotrexate, cardiovascular disease, inflammation, systematic literature review

Identifiers

Local EPrints ID: 73199
URI: http://eprints.soton.ac.uk/id/eprint/73199
ISSN: 1462-0324
PURE UUID: d2dfb6a5-7066-4954-b6ad-3d2892500882
ORCID for Janis Baird: ORCID iD orcid.org/0000-0002-4039-4361

Catalogue record

Date deposited: 03 Mar 2010
Last modified: 18 Jul 2017 23:51

Export record

Altmetrics

Contributors

Author: Sarah L. Westlake
Author: Alexandra N. Colebatch
Author: Janis Baird ORCID iD
Author: Patrick Kiely
Author: Mark Quinn
Author: Ernest Choy
Author: Andrew J.K. Ostor

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×